BioSpace News Archive

Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced results of an expansion cohort of a 16-week Phase 2a clinical trial, Cohort C, evaluating efruxifermin (EFX) in the treatment of adult patients with cirrhotic nonalcoholic steatohepatitis (NASH

Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ Peptide Drug Conjugate tumor targeting platform, announced that the U.S. Food and Drug Administration has provided the green light regarding the Investigational New Drug application for CBX-12, the company’s lead therapeutic candidate.

Oakrum Pharma, LLC, in collaboration with n, announced the U.S. approval of a generic version of JADENU®1 Sprinkle in 90mg, 180mg, and 360mg strengths.

Sutro Biopharma, Inc. announced the strengthening of key leadership roles including the promotion of David Pauling, J.D., M.A., to General Counsel, the promotion of Robert Kiss, Ph.D., to Senior Vice President, Process and Analytical Development, and the appointment of Ana Oaknin Benzaquen, M.D., Ph.D., to Sutro’s Clinical Advisory Board.

- Combined company will generate well over $100 million of ARR and signals a significant transformation in the future of software and data management in research labs. - Enabling over one million scientists to improve research and lab efficiency. - Facilitating rapid data access and exchange between scientists around the world, ultimately giving customers a competitive edge.

Blade Therapeutics, Inc., a biopharmaceutical company committed to revolutionizing the treatment of fibrotic diseases, announced the appointment of Jean-Frédéric Viret, Ph.D., as Chief Financial Officer effective immediately.

XyloCor Therapeutics, a private clinical-stage biopharmaceutical company focused on the development of gene therapy for the significant unmet patient needs in advanced coronary artery disease, announced the closing of an additional $22.6 million financing.

Landmark REVITA-T2Di study will assess potential of outpatient Revita DMR treatment to eliminate need for daily insulin

Proceeds to Support Pivotal Program of AU-011 for the First Line Treatment of Choroidal Melanoma and Expansion of Virus-like Drug Conjugate (VDC) Platform in additional Ocular Oncology Indications and Solid Tumors

Biotech company SaNOtize Research & Development Corp., announced that it has received interim approval to sell its Nitric Oxide Nasal Spray, which protects users from viruses that enter the body through the upper nasal pathways, to the public in pharmacies in Israel, and has been registered to begin sales of NONS in New Zealand.